Search
for
Sort by
Research 31–60 of 532
- Apremilast is efficacious in refractory alopecia areata
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
- The ‘bald’ phenotype (androgenetic alopecia) is caused by the high glycaemic, high cholesterol and low mineral ‘western diet’
- Therapeutic use of caffeine in dermatology: A literature review
- Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
- Alopecia areata: from pathophysiology to therapeutic innovation
- Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
- Wider clinical applications of fumaric acid esters: A useful option in psoriasis patients with multiple sclerosis
- Approaching Erectile Dysfunction in Dermatology Patients
- 873 The effect of Cilostazol on hair growth: A novel therapeutic option for the treatment of hair loss
- Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport
- The urologic impact of long-term finasteride 1-mg use for androgenic alopecia: a matched-cohort database analysis
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
- Medical management of benign prostatic hyperplasia
- Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting
- The pharmacological treatment of alopecia areata
- 1113 Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via Ly6 antigen for psoriasiform dermatitis alleviation
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- 22-Year-Old Male with Several Discrete Patches of Hair Loss
- Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
- Treatment of actinic cheilitis with ingenol mebutate gel: Experience in four patients
- Study of QuantiFERON’S conversion/reversal phenomena in patients with psoriasis during biological treatment
- Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
- FDA approves label addition for PDE-5 inhibitor
- Anti‐hair loss effect of a shampoo containing caffeine and adenosine
- Caffeine and Its Role in Regulation the Androgenetic Alopecia.
- 8 Finasteride-Associated Suicide and Depression in Men Treated for Hypogonadism and Impotence